Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Clinical trial NCT04732494 · COMPLETED

Trial details

NCT number: NCT04732494
Sponsor: BeiGene
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Esophageal Squamous Cell Carcinoma

Start date: 2021-03-31
Primary completion: 2023-02-01
Enrollment: 125

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.